AA
PCVX icon

AlphaCentric Advisors’s Vaxcyte PCVX Stock Holding History

AlphaCentric Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$161K Buy
+1,965
New +$195K 0.16% 138

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaCentric Advisors's PCVX Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Vaxcyte (PCVX) in Q4 2024: 1,965 shares worth $161K. The stake represents 0.16% of the portfolio and ranks #138 among its holdings.

323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • AlphaCentric Advisors held 1,965 shares of Vaxcyte worth $161K as of Q4 2024.
  • Vaxcyte was a new AlphaCentric Advisors position in Q4 2024.
  • Vaxcyte made up 0.16% of AlphaCentric Advisors's portfolio in Q4 2024, its #138 holding.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.